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Sir,
We have read with great interest the study by Kontos et al (2010)
in British Journal of Cancer about the use of L-DOPA decarboxy-
lase as a prognostic marker for colorectal adenocarcinoma.
To assess the expression level of L-DOPA decarboxylase
transcripts, the authors have performed qRT-PCR using GAPDH
as the dedicated housekeeping gene (HKG) to normalise their
results. However, no results concerning the stability of GAPDH
that has lead to its use as the best housekeeper in their model
system were available.
We have recently shown on human cell lines that choosing
an unstable internal control gene could generate dramatic
misinterpretations (Caradec et al, 2010a). In our study, and in
our conditions, GAPDH was one of the most variable HKG so
far impairing its use as a relevant normaliser. As this gene is likely
to be emblematical to normalise gene expression results, we have
developed a specific qRT-PCR with calibration curve to specifically
study GAPDH expression in different cell lines grown with various
hypoxic conditions. Our results unambiguously showed that
GAPDH expression varies according to oxygen tension. We have
also analysed GAPDH variability comparing meta-analysis data
from microarray experiments on human samples available online
(https://www.oncomine.com/resource/login.html). Using Oncomine
4.3, a powerful tool allowing rapid gene expression comparison
between healthy and/or tumour human samples, we report here that
GAPDH variability differs largely from one study to another and
more importantly may largely vary between patients in a given study
(Figure 1). As, aside still unidentified factors, hypoxia can be consi-
dered as a major one to have a critical role in cancer development,
especially in colorectal cancer (Baba et al, 2010), we would be
interested in learning how Kontos et al have tested HKGs variability
in their system and found GAPDH to be the most relevant.
Another unclear point concerns qRT-PCR Ct intervals between
GAPDH and L-DOPA target gene amplification. Indeed, the study
results of Kontos et al. showed a DCt equal to 13 (Ct (GAPDH)
15, Ct (L-DOPA) 28), signifying that GAPDH transcripts
are likely to be expressed 2
13 (8200) times higher than those
encoding L-DOPA. As we stressed this particular point very
recently, discussing about the use of r18S as a normaliser (Caradec
et al, 2010b), we would be very interested to know Kontos et al.
opinion about the accuracy of such disproportion.
Definitely, the choice of a valid HKG set will determine the
relevance of the results that will be further interpreted, and so it
should be seriously considered.
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Figure 1 GAPDH fold change in different colon adenocarcinoma studies
(Graudens et al, 2006; Clarke et al, 2003; Notterman et al, 2001 and
Bittner, not published (International Genomics Consortium, Expression
Project for Oncology - Colon Samples, http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc¼GSE2109)). Zero on the bar chart scale represents no change,
with each increment on the scale representing a two-fold difference. In
Bittner study, it means that the observed 5.922 interval between maximal
and minimal values corresponds to a 2
5.922, i.e., 60 GAPDH fold change.
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